Society: Don't Blame the Mothers
By Sarah S. Richardson, Cynthia R. Daniels, Matthew W. Gillman, Janet Golden, Rebecca Kukla, Christopher Kuzawa & Janet Rich-Edwards,
Nature
| 08. 13. 2014
From folk medicine to popular culture, there is an abiding fascination with how the experiences of pregnant women imprint on their descendants. The latest wave in this discussion flows from studies of epigenetics — analyses of heritable changes to DNA that affect gene activity but not nucleotide sequence. Such DNA modification has been implicated in a child's future risk of obesity, diseases such as diabetes, and poor response to stress.
Headlines in the press reveal how these findings are often simplified to focus on the maternal impact: 'Mother's diet during pregnancy alters baby's DNA' (BBC), 'Grandma's Experiences Leave a Mark on Your Genes' (Discover), and 'Pregnant 9/11 survivors transmitted trauma to their children' (The Guardian). Factors such as the paternal contribution, family life and social environment receive less attention.
Questions about the long shadow of the uterine environment are part of a burgeoning field known as developmental origins of health and disease (DOHaD)1. For example, one study revealed2 that 45% of children born to women with type 2 diabetes develop diabetes by their...
Related Articles
By Sarah Zhang, The Atlantic | 03.18.2024
People are discovering the truth about their biological parents with DNA—and learning that incest is far more common than many think.
When Steve Edsel was a boy, his adoptive parents kept a scrapbook of newspaper clippings in their bedroom closet...
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...
By Carl Zimmer, The New York Times | 03.10.2024
In 1889, a French doctor named Francois-Gilbert Viault climbed down from a mountain in the Andes, drew blood from his arm and inspected it under a microscope. Dr. Viault’s red blood cells, which ferry oxygen, had surged 42 percent. He...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...